Atacicept for IgAN & 96-Week ORIGIN Data, with Jonathan Barratt, PhD, at Kidney Week 2024
Update: 2024-10-27
Description
Live from Kidney Week 2024!
Hosts Neuen and Wadhwani are joined by Prof. Jonathan Barratt to discuss atacicept's 96-week data from ORIGIN OLE, which he presented as a late-breaker at the meeting.
Video Version Here
Results of the study indicate atacicept use was associated with sustained reductions across multiple endpoints of interest, including a 66% (SE, 2%) mean reduction in Gd-IgA1 levels, a reduction in percentage of patients with hematuria from baseline (percentage change, 75%; 95% CI, -87% to -59%), and a mean reduction in UPCR of 52% (SE, 5%). The mean eGFR annualized slope was just -0.6 (SE, 0.5) mL/min/1.73m2 per year.
As the discussion unfolds, Barratt explains atacicept’s unique approach of targeting disease-causing cytokines and highlights the drug’s practical benefit as a weekly self-administered injection, making it accessible for long-term patient use. The conversation wraps up with insights into the global impact of ongoing phase 3 trials, the sponsor’s commitment to extended access, and how these steps could redefine outcomes for patients with IgA nephropathy.
Chapters
00:00 – Start
01:30 – Understanding Atacicept and Its Mechanism
05:00 – Phase 2 Trial Results and Clinical Impact
10:00 – Advantages of At-Home Therapy and Patient Adherence
13:00 – Future of IgA Nephropathy Treatment and Phase 3 Trials
Relevant disclosures of interest for Barratt included Argenx, Calliditas Therapeutics, Chinook Therapeutics, Galapagos NV, GSK, Novartis, and Travere Therapeutics. Relevant disclosures for Neuen include AstraZeneca, Bayer, Boehringer and Ingelheim, Janssen, and others. Relevant disclosures for Wadhwani include the National Institute of Diabetes and Digestive and Kidney Diseases, GSK, Calliditas and Travere Therapeutics.
Hosts Neuen and Wadhwani are joined by Prof. Jonathan Barratt to discuss atacicept's 96-week data from ORIGIN OLE, which he presented as a late-breaker at the meeting.
Video Version Here
Results of the study indicate atacicept use was associated with sustained reductions across multiple endpoints of interest, including a 66% (SE, 2%) mean reduction in Gd-IgA1 levels, a reduction in percentage of patients with hematuria from baseline (percentage change, 75%; 95% CI, -87% to -59%), and a mean reduction in UPCR of 52% (SE, 5%). The mean eGFR annualized slope was just -0.6 (SE, 0.5) mL/min/1.73m2 per year.
As the discussion unfolds, Barratt explains atacicept’s unique approach of targeting disease-causing cytokines and highlights the drug’s practical benefit as a weekly self-administered injection, making it accessible for long-term patient use. The conversation wraps up with insights into the global impact of ongoing phase 3 trials, the sponsor’s commitment to extended access, and how these steps could redefine outcomes for patients with IgA nephropathy.
Chapters
00:00 – Start
01:30 – Understanding Atacicept and Its Mechanism
05:00 – Phase 2 Trial Results and Clinical Impact
10:00 – Advantages of At-Home Therapy and Patient Adherence
13:00 – Future of IgA Nephropathy Treatment and Phase 3 Trials
Relevant disclosures of interest for Barratt included Argenx, Calliditas Therapeutics, Chinook Therapeutics, Galapagos NV, GSK, Novartis, and Travere Therapeutics. Relevant disclosures for Neuen include AstraZeneca, Bayer, Boehringer and Ingelheim, Janssen, and others. Relevant disclosures for Wadhwani include the National Institute of Diabetes and Digestive and Kidney Diseases, GSK, Calliditas and Travere Therapeutics.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
